Products Categories
CAS No.: | 65-19-0 |
---|---|
Name: | Yohimbine hydrochloride |
Molecular Structure: | |
|
|
Formula: | C21H26N2O3.ClH |
Molecular Weight: | 390.91 |
Synonyms: | Yohimban-16-carboxylicacid, 17-hydroxy-, methyl ester, monohydrochloride, (16a,17a)- (9CI);Yohimban-16a-carboxylic acid, 17a-hydroxy-, methyl ester, monohydrochloride (8CI);Actibine;Antagonil;Yohimbe;Yohimbine monohydrochloride;Yohimex;Yohimbe Bark Extract;Yohimbine hydrochloride; |
EINECS: | 200-600-4 |
Melting Point: | 288-290 °C (dec.)(lit.) |
Boiling Point: | 543 °C at 760 mmHg |
Flash Point: | 282.2 °C |
Appearance: | Very slightly yellow needles. |
Hazard Symbols: |
![]() |
Risk Codes: | 23/24/25-33-23/24 |
Safety: | 22-36/37/39-45-24/25 |
PSA: | 65.56000 |
LogP: | 3.38700 |
yohimbine
2α,7α-dihydroyohimbine
Conditions | Yield |
---|---|
With sodium cyanoborohydride In trifluoroacetic acid | 100% |
With sodium cyanoborohydride In trifluoroacetic acid at 20℃; for 3h; | 100% |
yohimbine
1-hydroxyyohimbine
Conditions | Yield |
---|---|
Stage #1: yohimbine With sodium cyanoborohydride In trifluoroacetic acid at 20℃; for 3h; Stage #2: With sodium tungstate; dihydrogen peroxide In methanol; water at 0℃; for 1h; Further stages.; | 86% |
Multi-step reaction with 2 steps 1: 100 percent / NaBH3CN / trifluoroacetic acid 2: 86 percent / Na2WO4*2H2O; 30 percent H2O2 View Scheme |
yohimbine
A
10-hydroxy-yohimbine
Conditions | Yield |
---|---|
With sodium persulfate; hydrogen fluoride; antimony pentafluoride at -35℃; for 1h; | A 32 % Chromat. B 23 % Chromat. C 11 % Chromat. D 3 % Chromat. |
yohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: 99 percent / K2CO3 / dimethylformamide / 0.5 h / 20 °C View Scheme |
yohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: Cs2CO3 / methanol / 0.33 h / 20 °C 2.2: 99 percent / dimethylformamide / 1 h / 20 °C View Scheme |
yohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: Cs2CO3 / methanol / 0.33 h / 20 °C 2.2: 99 percent / dimethylformamide / 1 h / 20 °C View Scheme |
yohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: Cs2CO3 / methanol / 0.33 h / 20 °C 2.2: 11 percent / dimethylformamide / 1 h / 20 °C View Scheme |
yohimbine
Na-methoxyyohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: 77 percent / methanol; diethyl ether / 1 h / 0 °C View Scheme | |
Multi-step reaction with 3 steps 1: 100 percent / NaBH3CN / trifluoroacetic acid 2: 86 percent / Na2WO4*2H2O; 30 percent H2O2 3: 77 percent / methanol View Scheme |
yohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: 99 percent / K2CO3 / dimethylformamide / 0.5 h / 20 °C View Scheme | |
Multi-step reaction with 3 steps 1: 100 percent / NaBH3CN / trifluoroacetic acid 2: 86 percent / Na2WO4*2H2O; 30 percent H2O2 3: 93 percent / K2CO3 / dimethylformamide View Scheme |
yohimbine
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1.1: NaBH3CN / trifluoroacetic acid / 3 h / 20 °C 1.2: 86 percent / Na2WO4*2H2O; H2O2 / H2O; methanol / 1 h / 0 °C 2.1: 93 percent / K2CO3 / dimethylformamide / 0.5 h / 20 °C View Scheme | |
Multi-step reaction with 3 steps 1: 100 percent / NaBH3CN / trifluoroacetic acid 2: 86 percent / Na2WO4*2H2O; 30 percent H2O2 3: 99 percent / K2CO3 / dimethylformamide View Scheme |
What can I do for you?
Get Best Price
The CAS registry number of Yohimbine hydrochloride is 65-19-0. With the EINECS registry number 200-600-4, the IUPAC name of it is methyl (16α,17α)-17-hydroxyyohimban-16-carboxylate hydrochloride (1:1). In addition, the molecular formula is C21H26N2O3.ClH and the molecular weight is 354.44. It is a kind of white to slightly yellow powder and belongs to the classes of Alkaloids; Biochemistry; Indole Alkaloids; Natural Plant Extract; Adrenoceptor; Adrenoceptors. What's more, it is a plant alkaloid with alpha-2-adrenergic blocking activity.
Physical properties about Yohimbine hydrochloride are: (1)ACD/LogP: 2.874; (2)ACD/LogD (pH 5.5): 0.11; (3)ACD/LogD (pH 7.4): 1.72; (4)ACD/BCF (pH 5.5): 1.00; (5)ACD/BCF (pH 7.4): 6.33; (6)ACD/KOC (pH 5.5): 1.51; (7)ACD/KOC (pH 7.4): 61.30; (8)#H bond acceptors: 5; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 3; (11)Index of Refraction: 1.661; (12)Molar Refractivity: 99.461 cm3; (13)Molar Volume: 269.114 cm3; (14)Polarizability: 39.429 10-24cm3; (15)Surface Tension: 63.3400001525879 dyne/cm; (16)Density: 1.317 g/cm3; (17)Flash Point: 282.184 °C; (18)Enthalpy of Vaporization: 86.429 kJ/mol; (19)Boiling Point: 542.979 °C at 760 mmHg
Uses of Yohimbine hydrochloride: it can be used for biochemical studies. And it is used as a mydriatic and in the treatment of erectile dysfunction. In addition, it can be used to get 2-hydroxy-1,2,3,4,4a,5,7,8,8a,13,13a,13b,14,14a-tetradecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester. This reaction will need reagent NaBH3CN and solvent trifluoroacetic acid. The yield is about 100%.
When you are using this chemical, please be cautious about it as the following:
It has danger of cumulative effects. And it is toxic by inhalation, in contact with skin and if swallowed. During using it, wear suitable protective clothing and gloves and eye/face protection and avoid contact with skin and eyes. And in case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.). In addition, do not breathe dust.
You can still convert the following datas into molecular structure:
(1)SMILES: Cl.O=C(OC)[C@@H]5[C@H]4C[C@H]3c2nc1ccccc1c2CCN3C[C@@H]4CC[C@@H]5O
(2)InChI: InChI=1/C21H26N2O3.ClH/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24;/h2-5,12,15,17-19,22,24H,6-11H2,1H3;1H/t12-,15-,17-,18-,19+;/m0./s1
(3)InChIKey: PIPZGJSEDRMUAW-VJDCAHTMBF
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LDLo | subcutaneous | 20mg/kg (20mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC | "Zur Pharmakologie der Yohimbealkaloide, Dissertation," Langer, J., Institute fuer Pharmakologie und Experimentelle Therapie der Universitat Breslau, Poland, 1932Vol. -, Pg. -, 1932. |
frog | LD50 | parenteral | 26mg/kg (26mg/kg) | Bulletin des Sciences Pharmacologiques. Vol. 47, Pg. 33, 1940. | |
frog | LD50 | subcutaneous | 34mg/kg (34mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 137, Pg. 305, 1943. | |
guinea pig | LD50 | intraperitoneal | 42mg/kg (42mg/kg) | Bulletin des Sciences Pharmacologiques. Vol. 47, Pg. 33, 1940. | |
man | TDLo | oral | 133ug/kg (.133mg/kg) | BEHAVIORAL: EUPHORIA | American Journal of Psychiatry. Vol. 141, Pg. 1267, 1984. |
mouse | LD50 | intraperitoneal | 45mg/kg (45mg/kg) | United States Patent Document. Vol. #4179510, | |
mouse | LD50 | oral | 40mg/kg (40mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Journal of Pharmaceutical Sciences. Vol. 51, Pg. 345, 1962. |
mouse | LD50 | subcutaneous | 43900ug/kg (43.9mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | British Journal of Pharmacology and Chemotherapy. Vol. 21, Pg. 51, 1963. |
mouse | LDLo | intravenous | 15mg/kg (15mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 50, Pg. 241, 1935. | |
rabbit | LDLo | intravenous | 5mg/kg (5mg/kg) | "Zur Pharmakologie der Yohimbealkaloide, Dissertation," Langer, J., Institute fuer Pharmakologie und Experimentelle Therapie der Universitat Breslau, Poland, 1932Vol. -, Pg. -, 1932. | |
rat | LD50 | intraperitoneal | 55mg/kg (55mg/kg) | AUTONOMIC NERVOUS SYSTEM: CENTRAL SYMPATHOLYTIC BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 110, Pg. 20, 1957. |
women | TDLo | oral | 400ug/kg (.4mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: EUPHORIA | American Journal of Psychiatry. Vol. 141, Pg. 1267, 1984. |